Akari Therapeutics Plc ROCE
Quel est le ROCE de Akari Therapeutics Plc?
Le ROCE de Akari Therapeutics Plc est -220.95%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur NASDAQ par rapport à Akari Therapeutics Plc
Que fait Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Entreprises avec roce similaire à Akari Therapeutics Plc
- BioCardia a ROCE de -224.64%
- Sunworks Inc a ROCE de -223.47%
- Soligenix Inc a ROCE de -223.00%
- Katoro Gold plc a ROCE de -222.81%
- DelMar Pharmaceuticals a ROCE de -222.47%
- Applied Therapeutics a ROCE de -222.43%
- Akari Therapeutics Plc a ROCE de -220.95%
- Dore Copper Mining a ROCE de -220.90%
- Applied Genetic Technologies Corp a ROCE de -219.90%
- Intrusion a ROCE de -219.55%
- Galera Therapeutics Inc a ROCE de -218.63%
- Lumos Pharma Inc a ROCE de -217.72%
- AutoWeb Inc a ROCE de -217.47%